Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Galmed Pharmaceuticals Ltd 주요 수익원은 Digital Brokerage Services이며, 최신 수익 발표에서 수익은 390,229,672입니다. 지역별로는 United States이 Galmed Pharmaceuticals Ltd의 주요 시장이며, 수익은 355,022,439입니다.
Galmed Pharmaceuticals Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Galmed Pharmaceuticals Ltd의 순손실은 $-7입니다.